Structure-based identification of novel human γ-glutamylcysteine synthetase inhibitors

Molecular Pharmacology

Volumn 71, Issue 4, 2007, Pages 1140-1147

  Hamilton, David ^a   Jian, Hui Wu ^a   Batist, Gerald ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GAMMA GLUTAMYLCYSTEINE SYNTHETASE INHIBITOR; GLUTATHIONE; MELPHALAN; UNCLASSIFIED DRUG;

ARTICLE; BIOASSAY; DATA BASE; DRUG BINDING; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOLECULAR MODEL; PRIORITY JOURNAL; SENSITIZATION; TUMOR IMMUNITY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DATABASES, FACTUAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE;

EID: 33947409143     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.024778     Document Type: Article

References (25)

1. Akan I, Akan S, Akca H, Savas B, and Ozben T (2005) Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and buthionine sulfoximine. Cancer Cell Int 5:22.
2. Chen X, Carystinos GD, and Batist G (1998) Potential for selective modulation of glutathione in cancer chemotherapy. Chem Biol Interact 112:263-275.
3. Davison K, Mann KK, Waxman S, and Miller WH Jr (2004) JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103:3496-3502.
4. Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, et al. (1996) Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 14:249-256.
5. Griffith OW (1982) Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 257:13704-13712.
6. Griffith OW and Friedman HS (1991) Glutathione and resistance to anticancer therapies in Synergism and Antagonism in Chemotherapy (Chou TC, Rideout DC eds) pp 245-285, Academic Press, San Diego.
7. Griffith OW and Mulcahy RT (1999) The enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase. Adv Enzymol Relat Areas Mol Biol 73:209-267.
8. Hamilton D, Wu JH, Alaoui-Jamali M, and Batist G (2003) A novel missense mutation in the γ-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathine production. Blood 102:725-730.
9. Hibi T, Nii H, Nakatsu T, Kimura A, Kato H, Hiratake J, Oda J (2004) Crystal structure of gamma-glutamylcysteine synthetase: insights into the mechanism of catalysis by a key enzyme for glutathione homeostasis. Proc Natl Acad Sci USA 101:15052-15057.
10. Hiratake J, Irie T, Tokutake N, and Oda JI (2002) Recognition of a cysteine substrate by E. coli γ-glutamylcysteine synthetase probed by sulfoximine-based transitionstate analogue inhibitors. Biosci Biotechnol Biochem 66:1500-1514.
11. Kyaw A, Maung-U K, and Toe T (1985) Determination of inorganic phosphate with molybdate and Triton X-100 without reduction. Anal Biochem 145:230-234.
12. Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, Hall AG, and Sargent JM (2002) Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Gynecol Oncol 85:298-304.
13. Lyne PD (2002) Structure-based virtual screening: an overview. Drug Discovery Today 7:1047-1055.
14. May MJ and Leaver CJ (1994) Arabidopsis thaliana γ-glutamylcysteine synthetase is structurally unrelated to mammalian, yeast, and Escherichia coli homologs. Proc Natl Acad Sci USA 91:10059-10063.
15. Meister A (1989) Metabolism and function of glutathione, in Glutathione: Chemistry, Biochemical and Medical Aspects (Dolphin D, Avramovich A, Poulson R eds) pp 367-474, John Wiley & Sons, Inc., New York.
16. Meister A and Anderson ME (1983) Glutathione metabolism and function. Annu Rev Biochem 52:711-760.
17. Perola E, Xu K, Kollmeyer TM, Kaufmann SH, Prendergast FG, and Pang YP (2000) Successful virtual screening of a chemical database for Farnesyltransferase inhibitor leads. J Med Chem 43:401.
18. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, and Pu YS (2005) Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 65:8455-8460.
19. Rappa G, Gamcsik MP, Mitina RL, Baum C, Fodstad O, and Lorico A (2003) Retroviral transfer of MRP1 and gamma-glutamyl cysteine synthetase modulates cell sensitivity to L-buthionine-S,R-sulphoximine (BSO): new rationale for the use of BSO in cancer therapy. Eur J Cancer 39:120-128.
20. Russell RB and Sternberg MJ (1997) Two new examples of protein structural similarities within the structure-function twilight zone. Protein Eng 10:333-338.
21. Tokutake N, Hiratake J, Katoh M, Irie T, Kato H, and Oda JI (1998) Design, synthesis and evaluation of transition-state analogue inhibitors of Escherichia coli γ-glutamylcysteine synthetase. Bioorg Med Chem 6:1935-1953.
22. Torky AR, Stehfest E, Viehweger K, Taege C, and Foth H (2005) Immunohistochemical detection of MRPs in human lung cells in culture. Toxicology 207:437-450.
23. Wu JH, Batist G, and Zamir LO (2001) Identification of a novel steroid derivative, NSC12983, as a Paclitaxel-like tubulin assembly promoter by 3-D virtual screening. Anticancer Drug Des 16:129-133.
24. Yoshida A, Takemura H, Inoue H, Miyashita T, and Ueda T (2006) Inhibition of glutathione synthesis overcomes Bcl-2-mediated topoisomerase inhibitor resistance and induces nonapoptotic cell death via mitochondrial-independent pathway. Cancer Res 66:5772-5780.
25. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, et al. (1999) Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 91:743-745.